Arch-backed HiberCell launches with over $60M to target dormant cancer cells

HiberCell Inc. (New York, N.Y.) launched Thursday with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and

Read the full 261 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE